Diagnostic Rentability of Screening for Associated Conditions in Calcium Pyrophosphate Deposition Disease Patients - Full Text View

Purpose

The purpose of this study is to determine whether thorough analytical evaluation is useful to diagnose metabolic conditions associated to calcium pyrophosphate deposition disease.

Condition

Chondrocalcinosis

ChemIDplus related topics:

Calcium gluconate

U.S. FDA Resources

Study Type:	Observational
Study Design:	Natural History, Longitudinal, Case Control, Prospective Study

Official Title:	Appraisal of the Diagnostic Rentability of Thorough Analytical Screening Searching Associated Conditions in Patients Newly Diagnosed With Calcium Pyrophosphate Dihydrate Deposition Disease

Further study details as provided by Sociedade Galega de Reumatoloxía:

Estimated Enrollment:	240
Study Start Date:	January 1997
Study Completion Date:	December 2006

Detailed Description:

The diagnostic usefulness of screening for hyperparathyroidism, hemochromatosis, hypothyroidism and hypophosphatasia in patients diagnosed with calcium pyrophosphate dihydrate (CPPD) deposition disease is uncertain.

Patients diagnosed with CPPD deposition disease were compared to patients with rheumatoid arthritis and psoriatic arthritis over a 9-year period. All patients were prospectively followed for at least 12 months. Serum calcium, phosphorus, alkaline phosphatase, thyroid-stimulating hormone, ferritin, iron, and total iron binding capacity were determined in all patients.

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients diagnosed as having calcium pyrophosphate dihydrate deposition disease.

Exclusion Criteria:

Patients mimicking a rheumatoid arthritis disease, with positive rheumatoid factor or with psoriasis.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00453128

Locations


Spain, Pontevedra
	Meixoeiro Hospital
	Vigo, Pontevedra, Spain, 36214

Sponsors and Collaborators

Sociedade Galega de Reumatoloxía

Investigators


Principal Investigator:	José M Pego-Reigosa, MD, PhD	Meixoeiro Hospital, Vigo (Pontevedra) SPAIN

More Information

Study ID Numbers:	SGR1
First Received:	March 26, 2007
Last Updated:	March 27, 2007
ClinicalTrials.gov Identifier:	NCT00453128
Health Authority:	Spain: Ministry of Health

Keywords provided by Sociedade Galega de Reumatoloxía:

Calcium Pyrophosphate

associated conditions

Study placed in the following topic categories:

Musculoskeletal Diseases

Chondrocalcinosis

Joint Diseases

Arthritis

Chondrocalcinosis 2

ClinicalTrials.gov processed this record on October 20, 2008

Sponsored by:	Sociedade Galega de Reumatoloxía
Information provided by:	Sociedade Galega de Reumatoloxía
ClinicalTrials.gov Identifier:	NCT00453128